

## **CERTIFICATE OF ANALYSIS No.: 2025-16385**

## CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8 1000 Ljubljana, Slovenija

## SAMPLE \* PHIX NERVES





Sample condition: SUITABLE Work order: 2025-112709 Sample received: 31/03/2025 2514004 Sample ID: Analysis ID: 2025\_103 Start of analysis: 31/03/2025 Sample type: Method ID: PHL\_RPC\_16C End of analysis: 01/04/2025 Viscous liquid Batch No .: \* 20250327 Method SOP: MET-LAB-001-08 Analyst: Valentina Malin \* Information provided by the client. Evnanded

CANNA	BINOID PROFILE	Concentration [% w/w]	uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	2.50	0.12	
CBDA	- Cannabidiolic acid	< LOQ	n/a	
CBGA	- Cannabigerolic acid	< LOQ	n/a	
CBG	- Cannabigerol	0.075	0.022	L
CBD	- Cannabidiol	24.7	1.2	
THCV	- Tetrahydrocannabivarin	0.392	0.063	I
CBN	- Cannabinol	< LOQ	n/a	
Δ <sup>9</sup> -THC	- Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
Δ <sup>8</sup> -THC	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
CBL	- Cannabicyclol	< LOQ	n/a	
CBC	- Cannabichromene	< LOQ	n/a	
Δ <sup>9</sup> -THCA	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
CBV	- Cannabivarin	0.064	0.014	<u> </u>
CBCA	- Cannabichromenic acid	< LOQ	n/a	
СВТ	- Cannabicitran	< LOQ	n/a	
CBE	- Cannabielsoin	0.065	0.018	ļ

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

Approved by:

01/04/2025

End of Certificate

mag. Valentina Malin Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar Chief Technology Officer